NeuroSense Therapeutics EBIT

The latest EBIT for NRSN is $-11M as of December 2025. That compares with $-9.9M in the prior-year period — down 11.9% year over year. That is above the sector sector average of $-77M. Investors often review this figure alongside NeuroSense Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NRSN's EBIT moved from $-9.9M to $-11M — a 11.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NeuroSense Therapeutics's operating scale or balance-sheet position.

Against its sector companies, NRSN currently prints $-11M for EBIT, while the sector average sits near $-77M. That is roughly 85.5% above the sector mean. Large gaps often invite a closer look at NeuroSense Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-11M for NRSN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-77M. Explore the charts below for those layers of context.

After noting NRSN's EBIT ($-11M), review year-over-year change from $-9.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.